In this study, we elucidated the potential of recombinant adeno-associated virus type-2 (rAAV-2) vectors for lung cancer gene therapy. Cell lines of the three major histological subtypes of non-small cell lung cancer (NSCLC) were highly susceptible for rAAV-2 showing transduction rates between 63.4 and 98.9%. In contrast, cell lines of small cell carcinomas were resistant to rAAV-2 infection. For restoration of p53 function in p53 deficient NSCLC, a rAAV-2 vector was constructed containing wt p53 cDNA. Following transduction with rAAV-p53, cell growth of all NSCLC cell lines was significantly reduced in a dose-dependent manner between 44 and 71.7% in comparison with rAAV-GFP transduced cells. The reduction of tumor cell growth was associated with increased apoptosis. Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Interestingly, the tumor cells surviving cisplatin and rAAV-p53 treatment were inhibited in their ability to form colonies as reflected by a reduction of colony growth between 57 and 90.4%. In conclusion, rAAV-2 vectors exhibit a strong tropism for NSCLC. Successful inhibition of tumor cell growth following transduction with a rAAV-p53 vector underlines the potential role of rAAV-2 in cancer gene therapy.
L ung cancer is the leading cause of cancer-related deaths with an increasing incidence worldwide. 1 One of the most frequently used agents in the treatment of lung cancer is cisplatin. Although cisplatin is able to induce apoptosis via p53 independent mechanisms, 2 cisplatin-mediated induction of p53 expression mainly triggers the apoptotic pathway. A loss of p53 function which can be found in more than 50% of tumors of lung cancer patients is responsible for the failure of cisplatinbased chemotherapy 3, 4 and is associated with a poor prognosis. 5 To overcome the treatment failure of cisplatin in lung cancer with altered p53 it seems to be useful to restore p53 in lung cancer cells. For introduction of a therapeutic gene such as p53, a vector is necessary with unique properties. One promising vehicle with great potential for gene delivery is the adeno-associated virus type-2. The nonpathogenic nature of the virus, infection of dividing and nondividing cells as well as the low immunogenicity are advantages in favor of adenoassociated virus type-2 (AAV-2). In this report, we examined the tropism of recombinant adeno-associated virus type-2 (rAAV-2) for a variety of lung cancer cell lines and identified all major histological NSCLC subtypes as promising targets for a AAV-2-mediated gene transfer. The potential of rAAV-2 vectors in cancer gene therapy was exemplified for the p53 gene, as a significant reduction of tumor cells was observed after transduction with rAAV-p53. In addition, we describe overadditive antitumor effects of a p53 encoding rAAV-2 vector in combination with cisplatin in lung cancer cells.
Material and methods

Cell lines and plasmids
Lung cancer cell lines H23, H322 (adenocarcinoma), H157 (squamous cell carcinoma), H1299, H460 (large-cell carcinoma) and H69, H82, H187, H526, H889 (small-cell carcinoma) were cultured in RPMI-1640 medium (Sigma, Deissenhofen, Germany) supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. All cell lines were cultured at 371C in 5% CO 2 . The lung cancer cell lines were obtained from the American Tissue Culture Collection. The human 293T cell line was cultured in DMEM containing the same supplements as stated above at 371C in 5% CO 2 . Vector plasmid pAAVgfp-AR6-and helper plasmid pDG have been previously described. 6 
Analysis of FGFR and aV integrin expression
For analysis of FGFR and aV integrin expression on SCLC cell line H69 and NSCLC cell line H157, 1 Â 10 5 cells were incubated with FITC-conjugated anti-CD51 (aV) antibody (Ab)(Clone AMF7; Immunotech, Marseille, France) or the nonconjugated Ab anti-FGFR-1 Ab (Sigma). Monoclonal PE-conjugated anti-rabbit (Sigma) was used as secondary Ab. Cells were subjected to FACS analysis using a FACSCalibur. After gating on viable cells, data were analyzed using the Becton Dickinson CELL QUEST software.
Construction of vector plasmid pAAV-p53
Plasmids were constructed using standard molecular biology techniques. The pAAV-gfp-AR6 plasmid kindly provided by Andrea Ho¨rster 6 was used as the backbone. pAAV-gfp-AR6 contains the gene for the enhanced green fluorescent protein (EGFP) and the HIV-1-directed antisense sequence AR6 under the control of the immediate-early HCMV promoter, a SV40 splice and a polyadenylation signal flanked by the inverted terminal repeats (ITRs) of the AAV-2 clone psub201. 7 pAAV-gfp-AR6 was digested with NheI (BioLabs, UK) and XbaI (BioLabs) excising the AR6 and EGFP transgene insert to yield the 5545 bp backbone of the plasmid. The pVP22-p53 plasmid containing the wild-type human p53 cDNA (kindly donated by Bernd Prisack, Onkologische Chemie, Du¨sseldorf, Germany) was digested with HindIII (BioLabs). The HindIII site was transformed into a NheI site using Klenow polymerase. After blunt-end religation the human wild-type p53 cDNA was excised from pVP22-p53 by digestion with NheI and XbaI yielding a 1188 bp fragment which was ligated with the pAAV-gfp-AR6 backbone. The new vector plasmid pAAV-p53 contained the gene for wt-p53 under the control of the immediateearly HCMV promoter, a SV40 splice and a polyadenylation signal flanked by the ITRs.
Production and purification of recombinant AAV-2 vector stocks
For preparation of rAAV-2 vector stocks, 1 Â 10 7 293T cells were cotransfected with 20 mg vector plasmid (pAAV-gfp-AR6-or pAAV-p53) and 20 mg helper plasmid pDG 8 by calcium phosphate precipitation. The helper plasmid pDG contained all AAV-2 (rep, cap) and adenoviral genes (E2A, E4, VA) necessary for rAAV-2 particle production. 293T cells were harvested 72 hours after transfection and were subjected to three cycles of freezing and thawing to release virus. The cell lysate was sonicated 10 times with pulsed 50% duty cycles at 200 W using a Branson Sonifier cell disrupter B-15 (Branson, Schwa¨bisch Gmuend, Germany) and spun down at 5000 g for 30 minutes. rAAV-2 preparations were purified and concentrated using the Iodixanol method as described. 9 Fractions were analyzed for rAAV-2 particles using FACS analysis as stated below.
Titration of infectious viral particles using fluorescenceactivated cell sorting Flow cytometry for titration of infectious rAAV-GFP particles was performed as previously described. 10 Briefly, 1 Â 10 5 HeLa cells were seeded in 500 ml medium in 24-well plates and 1, 2 or 5 ml of viral suspension was added to the cells. Cells were incubated at 371C for 48 hours. For detachment, 50 ml of 0.02% Trypsin/EDTA (Bio-Whittaker, Verviers, Belgium) was used. Trypsin was inactivated by adding 500 ml of 10% FCS/PBS. Following two washing steps with 1 ml PBS, cells were resuspended in 500 ml PBS. After determination of the total cell numbers, FACS analysis was performed using a Becton Dickinson FACSCalibur (Heidelberg, Germany) with a 2 W argon ion laser and EGFP fluorescence was measured using a 530/15 nm (FITC) band-pass filter. The percentage of green fluorescent cells was determined by FACS and was multiplied by the total cell number. Assuming that each EGFP-positive HeLa cell was infected by one rAAV-2 particle, viral titers were deduced from the percentage of transduced cells and diluted suspension.
Titration of genomic rAAV-2 titers using CMV promoterspecific quantitative real-time PCR (qPCR) Viral preparations were titrated by CMV promoterspecific qPCR as recently described.
11 qPCR was performed in a LightCycler using the FastStart DNA Master SYBR Green kit (Roche Molecular Biochemicals, Mannheim, Germany). Final concentrations in the PCR were: primers: 0.4 mM each, MgCl 2 : 5 mM, template: 2 ml in a final volume of 20 ml. PCR was performed with a 10 minute preincubation at 951C followed by 50 cycles of 15 seconds at 951C (denaturation), 5 seconds at 671C (annealing) and 10 seconds at 721C (amplification). PCR products were subjected to melting-curve analysis using the light-cycler system to exclude the amplification of unspecific products. Finally, the PCR products were analyzed by conventional agarose gel electrophoresis (1.5%) and the product length was 201 bp. Primers were synthesized by Thermo Hybaid GmbH, Interactiva Division Ulm, Germany. The following primers were used:
Western blot analysis
Western Blot was performed as described. 12 Briefly, H1299 cells were plated in 12-well plates and incubated with rAAV-p53 particles ranging between 250 and 1000 genomic copies per cell for 24 h. Cells were washed twice with ice-cold PBS, scraped off the plate and lysed in icecold cell lysis buffer (20 mM Tris-HCl, 1 mM CDTA, 1 mM EGTA, 1% Triton X-100, 0.1 M DTT, 0.5 M leupeptin, 0.1M PMSF). Protein samples were electrophoretically separated on 15% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Milipore, Schwalbach, Germany) for 1 hour. After blocking, membranes were incubated overnight at 41C with mouse anti-human p53 monoclonal antibody (Zymed, San Francisco; dilution 1:1000). A peroxidasecoupled rabbit anti-mouse secondary antibody was used for detection of primary antibodies (Amersham Biosciences, Freiburg, Germany; dilution 1:1000) for 1 hour. Immunocomplexes formed on the membrane were visualized with an enhanced chemiluminescence (ECL) kit (Amersham) according to the manufacturer's instructions.
Transduction experiments
Lung cancer cell lines (H1299, H157 and H23) were cultured in 24-well plates as described above and transduced with rAAV-GFP or rAAV-p53 at different concentrations. At 3 days after transduction, tumor cells were detached with trypsin/EDTA and resuspended with RPMI medium in a final volume of 1000 ml.
For cisplatin experiments, dose-response curves for cisplatin were determined by dilutions of cisplatin ranging from 1 to 0.1 mg/ml. A cisplatin concentration of 0.25 mg/ ml led to a mean cell growth inhibition of 53.3% (SD+22.5) in all three NSCLC cell lines (H199, H23, H157). This concentration was considered as suitable to evaluate subadditive, additive or overadditive growth inhibitory effects of rAAV-p53 and cisplatin on NSCLC cells. Performing transduction experiments using rAAV-2 and cisplatin, NSCLC cell lines were cultured in 24-well plates containing cisplatin in a concentration of 0.25 mg/ ml. Transduction was performed as described above. After 3 days of virus and cisplatin coincubation, cells were detached using trypsin/EDTA and resuspended with RPMI medium in a final volume of 1000 ml. Growth inhibition was assessed as stated below.
Assessment of viable cells
Cells were counted using a Neubauer counting chamber. The survival rate in percent was calculated by dividing the number of viable treated cells by the number of viable untreated control cells multiplied by 100. The viability of cells was assessed by trypane blue exclusion. Inhibition in percent was calculated by the following formula: inhibition in % ¼ 100%Àsurvival rate in %. All experiments were performed at least in triplicate.
Clonogenic assay
Clonogenic assays were performed seeding 5 Â 10 2 viable cells treated with rAAV-GFP alone, rAAV-p53 alone, cisplatin alone, rAAV-GFP in combination with cisplatin or rAAV-p53 in combination with cisplatin into 25 cm 2 flasks for 3 days. After 7 days, colonies were counted using a light microscope. Only colonies containing more than 50 cells were counted. The percentage of colonies was calculated by division of colony numbers derived from treated cells by those from untreated cells and multiplied by 100.
Apoptosis assay
The apoptosis rate was determined using an Annexin V binding assay as described. 13 Briefly, 48 hours after treatment of H1299 cells with rAAV-p53, rAAV-GFP and/or cisplatin, cells were suspended in 200 ml of Annexin V binding buffer (Pharmingen, Heidelberg, Germany). A volume of 100 ml was added to 10 ml of PE-conjugated control antibody (Pharmingen). The remaining 100 ml cell suspension was added to 10 ml of Annexin V-PE (Pharmingen). A volume of 10 ml of 7-amino-actinomycin D (7-AAD) (BD PharMingen, Germany) was added to PE-control and AnnexinV-PE sample in order to detect and exclude necrotic cells. After an incubation time of 15 minutes at room temperature, cells were washed and analyzed using a Becton Dickinson FACSCalibur (Heidelberg, Germany) with a 2 W argon ion laser. The proportion of apoptotic and necrotic cells, that is, Annexin V binding cells and 7-AAD binding cells, was assessed using the Cell Quest software (Becton Dickinson). Annexin positive cells showing no 7-AAD staining were regarded as apoptotic.
Statistical analysis
For statistical analysis, the Student's t-test was used. Statistical significance was defined as Po0.05.
Results
Tropism of rAAV-2 for lung cancer cells
In order to evaluate the tropism of rAAV-2 for lung cancer cells of different histological subtypes, 10 different lung cancer cell lines were transduced with a recombinant AAV-GFP vector with a MOI of 50 viral particles per cell. All cell lines of NSCLC such as adenocarcinoma (H23, H322), squamous cell carcinoma (H157) and largecell carcinoma (H1299, H460) were highly susceptible for rAAV-2 showing transduction rates between 63.4 and 98.9% with a mean transduction rate of 84.1% (SD719.9) 5 days after infection (Fig 1a, b) . In contrast, cell lines of SCLC (H69, H82, H187, H526, H889) were resistant to rAAV-2 infection showing a range of mean transduction rates between 1.1% (SD71.1) and 5.9% (SD73.0) 5 days after transduction. In order to explain the differences of tropism, the expression of the AAV-2 co-receptors FGFR-1 and aV integrin necessary for viral
cell entry was examined on the rAAV-2 resistant SCLC cell line H69 as well as on the NSCLC cell line H157 showing the highest transduction rate of 98.9%. As assessed by flow cytometry, the SCLC cell line H69 showed no rAAV-2 coreceptor expression, whereas FGFR-1 and aV integrin expression was present on all H157 cells (Fig 1c) .
Successful rAAV-2-mediated transfer of the p53 gene
A high susceptibility of rAAV-2 was observed for NSCLC cells using a rAAV-GFP vector. In order to generate a therapeutic rAAV-2 vector, we constructed an adenoassociated vector carrying the p53 gene. After infection of the p53-negative cell line H1299 with rAAV-p53 using MOIs between 250 and 1000 genomic particles per cell, restoration of p53 expression was detected by immunoblotting (Fig 2) . (Fig 3a, b) . Proliferation was not impaired in tumor cells infected with a rAAV-GFP control.
Induction of apoptosis by rAAV-p53
Expression of p53 can induce cell-cycle arrest and apoptosis. Therefore, induction of apoptosis in NSCLC tumor cells was examined using the new vector rAAVp53. H1299 cells were incubated with 6 Â 10 2 rAAV-p53 or rAAV-GFP particles per cell for 2 days and analyzed for apoptotic cells using an annexin V-binding assay with exclusion of necrotic cells using the 7-AAD nucleic acid dye. Cisplatin was used as a positive control with a concentration of 0.25 mg/ml. Untreated cells showed a rAAV p53 gene transfer in lung cancer cells U-P Rohr et al spontaneous apoptosis rate of 5.4% (SD +2.9%) while cisplatin increased the rate of apoptotic cells to 24.2% (SD +1.7%). Cells that had been infected with the control vector rAAV-GFP had an apoptosis rate of 7.7% (SD +1.9%). Cells treated with the therapeutic vector rAAV-p53 showed the highest apoptosis rate of 28.3% (SD+4.3%) (Fig 4) .
Cytotoxic effect of rAAV-p53 in combination with cisplatin
In order to enhance the chemosensitivity of NSCLCs by introduction of p53, we tested the combination of rAAVp53 with the DNA-damaging agent cisplatin. The growth of H1299, H23 and H157 was reduced by 64.5% (SD716.9), 62.7% (SD718.2) and 32.6% (SD713.5), respectively, using cisplatin alone (Fig 5a, b) . Combination of rAAV-p53 and cisplatin led to a further inhibition of growth in a dose-dependent manner. The mean growth inhibition of H1299, H23 and H157 cells treated with a combination of cisplatin and increasing doses of rAAVp53 were between 66.3-90.7%, 70.1-91% and 41.9-81%, 
respectively. The reduction of the tumor cell number following combined vector and cisplatin treatment was statistically significant for intermediate and high vector concentrations compared to the control rAAV-GFP. In an attempt to evaluate subadditive, additive or overadditive growth inhibitory effects of rAAV-p53 and cisplatin on NSCLC cells, we first performed experiments using the single agents. Based on these results we calculated hypothetical combined survival rates by adding the effects of cisplatin and rAAV-p53 given as single agents. The calculated survival rates were compared with the measured survival rates of the combined treatment. In H1299 and H157 additive effects were found with survival rates almost identical to the calculated results. In contrast, the inhibition was overadditive in cell line H23. This was reflected by a growth inhibition of 91% which was higher than the expected growth inhibition of 79% when simply adding the effects of cisplatin or rAAV-p53 given as single agents.
Effects of rAAV-p53 and cisplatin on clonogenic growth
Following combined rAAV-p53 and cisplatin treatment of NSCLC between 9 and 19% of the tumor cells still survived. Therefore, we were interested in the ability of those surviving tumor cells for clonogenic growth. As assessed by trypane blue exclusion, an equivalent number of cells that had survived the treatment of cisplatin (with or without rAAV-GFP or rAAV-p53) was washed and placed in a cell culture plate with regular cell culture medium. After 7 days, the colonies were counted. Generally, cells surviving combined cisplatin and rAAVp53 treatment had a significantly inhibited ability to form colonies in comparison with cells without pretreatment. The inhibitory effects were overadditive which is best exemplified for cell line H157. Neither a treatment of cells with cisplatin or rAAV-p53 as single agents had a significant inhibitory effect on the development of colonies compared to the untreated cells. In contrast, the combined treatment led to a 57% (SD79.5%) inhibition of clonogenic colony growth (Fig 6) . The overadditive inhibitory effect on colony growth was also seen for cell line H1299 with a colony reduction of 90.4% (SD73.41%).
Discussion
In this study, we show that rAAV-2 vectors have a strong tropism for NSCLCs. All NSCLCs were highly susceptible for rAAV-2 with transduction rates between 60 and 98.9%. In contrast, SCLCs were resistant to rAAV-2 infection. Those differences of lung cancer susceptibility to rAAV are most likely explained by receptor status of the cells. rAAV-2 susceptible NSCLC cells expressed the essential coreceptors for viral internalization FGFR-1 and alphaV-integrin 14, 15 while SCLC cells did not. Most common viral vectors in gene therapy have been recombinant retroviruses and adenoviruses. However, the vectors can be associated with serious adverse events due to the biologic behavior of the vector system. Earlygeneration adenoviral vectors were highly immunogenic possibly causing a systemic inflammatory response syndrome (SIRS) leading to multiple organ failure. 16 Genes carried by retroviral vectors are randomly integrated into the genome of the cell. This potentially leads to insertional mutagenesis which is currently under investigation in a French trial of gene therapy for Xlinked severe combined immune deficiency in which one out of 11 patients developed a monoclonal gamma-delta T-cell lymphoproliferative disorder 30 months after retroviral vector treatment (Press release of the European Society of Gene Therapy, November 2002).
In comparison to wild-type AAV-2, recombinant AAV-2 vectors have lost the ability for site-specific integration into chromosome 19 due to the removal of the rep-coding sequences. Extra-chromosomal, not integrated, genomes are the major intracellular form of recombinant AAV, which greatly decreases the potential risk of vector-related mutagenesis. Further, AAV-2 is not associated with any human disease and the weak immunogenicity of AAV-2 enables a safe vector administration into a target-tissue for several times as shown in a clinical study for patients with haemophilia B. 17 Finally, AAV-2 has a high transduction capacity in primary human cells. 10 Although rAAV vectors play an important role in the substitutional rAAV p53 gene transfer in lung cancer cells U-P Rohr et al therapy of genetic disorders, the potential of rAAV-2 for cancer gene therapy was disregarded so far. For a cancer therapy, wild-type AAV-2 offers some unique properties. Next to a direct antioncogenic effect of wt-AAV, 18, 19 infection with wt-AAV-2-prevented chemotherapy-related toxic side effects 20 and mediated sensitivity to chemotherapy. 21, 22 Moreover, infection and gene expression occur in both nondividing and dividing cells. As a result, we were interested if recombinant AAV-2 vectors can play a role in the treatment of lung cancer. Therefore, a rAAV-2 vector was constructed containing the wt-p53 gene. This tumor suppressor gene was chosen since p53 functions are well documented 23 and growth inhibitory effects were already shown for lung, 24 colorectal 25 or pancreatic 26 cancer cell lines using an adenovirus-mediated gene transfer. After transduction of lung cancer cell lines using our rAAVp53, p53 was successfully restored and a significant growth inhibition ranging from 44 to 72% was seen in H23, H157 and H1299 NSCLC cell lines. In contrast, the control vector rAAV-GFP had no inhibitory effect demonstrating the specific effect of rAAV-2-mediated wt-p53 gene transfer. As expected, the inhibitory effect of rAAV-p53 was mediated by apoptosis. 27 Encouraged from the results that wild-type AAV-2 itself as well as p53 can enhance the sensitivity to chemotherapy, we were interested if recombinant AAV-2 vectors have the same ability. Combined treatment of NSCLC cell lines with cisplatin and recombinant AAV-p53 led to additive or overadditive inhibitory effects on lung tumor cells with a growth inhibition between 81 and 91%. In addition, the surviving tumor cells were significantly hampered to form colonies without any further treatment showing a long-term effect even after removement of the cytotoxic drugs. However, no growth inhibitory effects were seen for a combination of cisplatin and the control vector rAAV-GFP in comparison to cisplatin alone. The results implicate that recombinant AAV-2 vectors have lost the ability to sensitize NSCLC tumor cells to chemotherapy as described for wild-type AAV-2. The lack of rep/cap genes in recombinant AAV-2 vectors is the most likely explanation for the missing sensitizing effect on tumor cells. The overadditive synergistic effect of cisplatin and recombinant AAV-p53 in NSCLC cell lines can be explained by a sustained expression of proapoptotic p53 during the clonogenic assay and DNA damage induced by cisplatin during pretreatment.
Despite the encouraging results, rAAV-2 vector delivery might be difficult. Tropism of rAAV-2 is so far too broad for intravenous application. Moreover, more than 90% of humans have been exposed to wild-type AAV-2 and, therefore, carry antibodies against the virus. Thus, administration or readministration of rAAV-2 in humans could be problematic. Next to direct intratumoral injection, new ways of applications such as an effective aerosolic vector inhalation for local administration would be beneficial or, alternatively, rAAV-2 mutants could be designed mediating a specific tropism in NSCLC cells.
In summary, we have demonstrated for the first time to our knowledge that NSCLC cells are prime targets for AAV-2. A new recombinant AAV-2 vector containing the cDNA for p53 induced a significant growth inhibition and had a chemosensitizing effect. The extent of rAAV-2 mediated p53 tumor cell death and the synergy with DNA-damaging agents such as cisplatin exemplifies the potential of rAAV-2 vectors for cancer therapy. The results encourage future efforts to develop additional rAAV-based vectors containing other tumor suppressor genes such as p16 or FHIT for lung cancer gene therapy.
